Skip to content

CATALYST PHARMACEUTICALS, INC.: 10-Q filed 2012-11-14

What CATALYST PHARMACEUTICALS, INC. reported in its quarterly report filed 2012-11-14 (fiscal Q3 2012): 29 published measures, 90 facts as tagged in accession 0001193125-12-470806.

This filing

Form
10-Q (quarterly report)
Filed
2012-11-14
Fiscal period
fiscal Q3 2012
Accession
0001193125-12-470806 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CATALYST PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-09-3012,105,212USD
At 2011-12-316,249,257USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-09-302,710,295USD
At 2011-12-312,488,559USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-09-309,394,917USD
At 2011-12-313,760,698USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-09-3011,973,860USD
At 2011-12-316,029,067USD
At 2011-09-302,151,432USD
At 2010-12-315,475,158USD
At 2002-01-03100,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-2,621,535USD92
2012-01-01 to 2012-09-30-3,999,801USD274
2002-01-04 to 2012-09-30-42,102,418USD3923
2011-07-01 to 2011-09-30-1,127,841USD92
2011-01-01 to 2011-09-30-4,039,128USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-09-30-3,546,580USD274
2002-01-04 to 2012-09-30-34,981,176USD3923
2011-01-01 to 2011-09-30-3,546,853USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2012-01-01 to 2012-09-306,882USD274
2002-01-04 to 2012-09-30109,708USD3923
2011-01-01 to 2011-09-301,800USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-09-309,498,255USD274
2002-01-04 to 2012-09-3046,964,744USD3923
2011-01-01 to 2011-09-302,228,634USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-01-01 to 2012-09-30-6,882USD274
2002-01-04 to 2012-09-30-109,708USD3923
2011-01-01 to 2011-09-30-2,005,507USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2012-09-30-42,102,418USD
At 2011-12-31-38,102,617USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-09-3010,832USD
At 2011-12-3112,186USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-07-01 to 2012-09-3045,585USD92
2012-01-01 to 2012-09-30135,765USD274
2002-01-04 to 2012-09-305,757,926USD3923
2011-07-01 to 2011-09-3048,985USD92
2011-01-01 to 2011-09-30167,812USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-1,283,713USD92
2012-01-01 to 2012-09-30-3,715,787USD274
2002-01-04 to 2012-09-30-42,976,285USD3923
2011-07-01 to 2011-09-30-1,131,010USD92
2011-01-01 to 2011-09-30-4,047,723USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-09-3012,085,492USD
At 2011-12-316,228,183USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-09-30753,330USD
At 2011-12-31833,801USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-09-30355,909USD
At 2011-12-31263,934USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2012-07-01 to 2012-09-301,283,713USD92
2012-01-01 to 2012-09-303,715,787USD274
2002-01-04 to 2012-09-3043,465,243USD3923
2011-07-01 to 2011-09-301,131,010USD92
2011-01-01 to 2011-09-304,047,723USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-07-01 to 2012-09-30654,837USD92
2012-01-01 to 2012-09-301,914,905USD274
2002-01-04 to 2012-09-3027,558,613USD3923
2011-07-01 to 2011-09-30614,137USD92
2011-01-01 to 2011-09-302,423,725USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-09-3034,741,520shares
At 2011-12-3124,701,420shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-09-3051,462,593USD
At 2011-12-3141,838,614USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2012-09-3078,142USD
At 2011-12-3171,260USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2012-09-3067,310USD
At 2011-12-3159,074USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2012-09-301,934,680USD
At 2011-12-311,645,240USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2012-09-30397,421USD
At 2011-12-31569,867USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2012-09-30111,632USD
At 2011-12-31199,116USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-07-01 to 2012-09-30628,876USD92
2012-01-01 to 2012-09-301,800,882USD274
2002-01-04 to 2012-09-3015,906,630USD3923
2011-07-01 to 2011-09-30516,873USD92
2011-01-01 to 2011-09-301,623,998USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2012-07-01 to 2012-09-302,725USD92
2012-01-01 to 2012-09-308,236USD274
2002-01-04 to 2012-09-30162,225USD3923
2011-07-01 to 2011-09-307,452USD92
2011-01-01 to 2011-09-3034,920USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2012-01-01 to 2012-09-309,498,255USD274
2002-01-04 to 2012-09-3043,072,557USD3923
2012-08-01 to 2012-08-316,000,000USD31
2012-05-01 to 2012-05-314,800,000USD31
2011-01-01 to 2011-09-302,228,634USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-09-3091,975USD274
2002-01-04 to 2012-09-30355,909USD3923
2011-01-01 to 2011-09-3068,105USD273

Inspect the source

Entity
CATALYST PHARMACEUTICALS, INC. / CIK 0001369568
Captured
2026-09-21T17:19:25.463Z
SEC response SHA-256
7cf76a511a9127dd31ed7d53955bbe348f790d8d7fd354d359e6674e7b2af9c9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001369568.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))